Daria Pašalić
Department of Medical Chemistry, Biochemistry and Clinical Chemistry
Zagreb University School of Medicine
Šalata ul 2.
10 000 Zagreb, Croatia
Phone +385 (1) 4590 205; +385 (1) 4566 940
E-mail: dariapasalic [at] gmail [dot] com

Useful links


Giuseppe Lippi1*, Ana-Maria Simundic2. Total quality in laboratory diagnostics. It's time to think outside the box. Biochemia Medica 2010;20(1):5-8.
1Clinical Chemistry and Hematology Laboratory, Academic Hospital of Parma, Italy and IFCC Working Group on Patient Safety
2University Department of Chemistry, School of Medicine, Faculty of Pharmacy and Biochemistry, Zagreb University, University Hospital “Sestre Milosrdnice”, Zagreb, Croatia
Corresponding author: glippi [at] ao [dot] pr [dot] it, ulippi [at] tin [dot] it, giuseppe [dot] lippi [at] univr [dot] it
Keywords: patient safety; laboratory diagnostics; preanalytical phase; errors; quality
Laboratory diagnostics is a fast-growing field, which provides a substantial contribution to the clinical decision making by supporting prevention, diagnosis, and therapeutic monitoring of most, if not all, human disorder (1). Quality and safety in diagnostic testing is, however, essential to furthering the goal of high-quality and safe healthcare, no other disciplines having such a prominent position in the patient safety solution than laboratory medicine (2). Whereas the total testing process is classically divided into three separate but sequential areas (i.e., preanalytical, analytical and postanalytical phases), a large body of evidence attests that most errors occur within the extra-analytical areas of testing, especially in the manually intensive preanalytical processes (3-7). As such, the preanalytical phase actually represents the most critical area to target for achieving major improvements in the total quality of laboratory diagnostics.
In this issue of Biochemia Medica, we publish an interesting cross-sectional survey study on self reported routines and procedures for the extra-analytical phase of laboratory practice in Croatia (8). Results were collected from 144 members of Croatian Chamber of Medical Biochemists (CCMB) using anonymous questionnaire with 20 Likert scaled questions testing self-reported frequency of preanalytical procedures. Questions were also divided in three groups (criteria of acceptance of sample, procedures of phlebotomy, test results reporting), which average score was calculated accordingly. The average overall score was globally satisfactory and no differences could be observed concerning the type of laboratory institution, professional degree or computer skills. The procedures of phlebotomy score achieved however, the lowest score and, disappointingly, nearly one fourth of the participants reported to never or rarely record nonconformities in their laboratories. The criteria of sample acceptance score was also significantly lower among medical biochemists with master degree than in laboratory professionals with a specialization in medical biochemistry. One original finding was that the private laboratories staff is apparently more focused on appropriate blood sampling procedures. This has been reasonably explained with the greater competition which private laboratories are inherently subjected in an open market, where major attention on blood sampling issues is necessary to prevent patient’s complains.
These results clearly point out the need for reinforced actions to improve the extra-analytical activities of the testing process, especially for collection of biological samples.
A similar national survey, sponsored by the Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC) and the Italian Society of Laboratory Medicine (SIMeL), was carried out in 2006, and yielded nearly identical results. Data analysis revealed a high degree of variability among laboratories for most preanalytical procedures (e.g., outpatient sampling, sample transportation). Only 31% of laboratories had some preanalytical steps automated at that time and 19% had no standardized protocols for sample transportation. The storage period and conditions for rerun/retest were also highly heterogeneous. In line with the findings of the CCMB survey, only 63% of laboratories had implemented a codified procedure for the management of unsuitable specimens, and half of them had as yet developed a standardized procedure for the management of unsuitable specimens (9). As compared with the Italian experience, where the questionnaire was developed to produce categorical answers (e.g., “yes” or “no”), the great advantage of the study published in Biochemia Medica is the methodological approach based on the Likert scale, which is the most widely used psychometric scale in survey research (10). When responding to a Likert questionnaire item, respondents specify their level of agreement to a statement by a graded answer (i.e., “never”, “rarely”, “often” and “always”), thereby producing ordinal data which enabled the calculation of a reliable score for each group of items.
Laboratory professionals, regulation bodies and the diagnostic industry as well have been focusing for decades on the analytical quality. Although not completely free from errors thus far, the analytical phase of testing is however subjected to a strict control using Internal Quality Control (IQC) materials, External Quality Assessment (EQA) schemes and calculation of measurement uncertainty (2,11,12). Regardless of a widespread awareness of the serious problems that might arise from the extra-analytical phases of testing, little has however been settled for reducing the uncertainty arising from this area. As such, the time has come to think outside the box, to place more focus on reliable strategies for a better control of those activities that inherently lie outside the traditional walls of the clinical laboratories. Although we all know that this is not simple, a starting point must be established. A first and foremost solution is the adoption of uniform reporting schemes for error events based on reliable quality indicators for both the analytical and extra-analytical phases of testing (13). As such, the recent project “Model of Quality Indicator”, undertaken by the Working Group, “Laboratory Errors and Patient Safety (WG-LEPS)” instituted by the division of Education and Management (EMD) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) must be regarded as a valuable foundation to promote and encourage investigations into errors in laboratory medicine, collect data available on this issue and recommend strategies and procedures for improving patient safety (14). Since the assessment of clinical outcomes in relation to laboratory diagnostics is even more challenging than establishing reliable quality indicators, the next step is the identification of those laboratory events arising transversally across the entire testing process that are more closely associated to a tangible harm for the patient. The development and implementation of reliable and universally agreed-upon laboratory “sentinel events” is thereby suited for this purpose, since it would allow to gain new knowledge about incidents and hold both providers and stakeholders accountable for patient safety (15,16).
The third step of this important process is the extension of the valuable concepts of IQC and EQA to the extra-analytical areas of testing (17). Although this will not be simple, there are already some valuable examples that an EQA program developed around the preanalytical phase might be feasible, practical and useful. Since the 1998, the Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC) has developed an EQA program for the preanalytical phase, focused on the analysis of causes for rejection of samples usually collected in laboratories and including two cycles per year. The participants are asked to register rejections and causes for rejection of routine or stat samples usually and locally collected at their laboratories. Data gathered throughout 10 blood cycles for the preanalytical phase have also been analyzed already, demonstrating that this approach might provide laboratories with a useful tool for an easier follow-up of their state-of-the-art and, incidentally, allowing them to implement continuous improvement (18). Most recently, a multicenter evaluation of the hemolysis index has been carried out to investigate the feasibility of establishing an EQA for managing hemolytic specimens in separate clinical laboratories. Reference sera containing varying amounts of hemolyzed blood and containing free hemoglobin contaminations ranging from 0 to 2.0 g/L were shipped to seven separate laboratories across Europe. The hemolysis index was then tested in triplicate on seven automated clinical chemistry systems. Interestingly, a satisfactory agreement of results was observed among the various analytical platforms and the discrepancies were remarkably attenuated after normalizing results according to the instrument-specific alert value (19). These results further support the usefulness of EQA programs for assessing and monitoring the total quality systems of clinical laboratories (20). The forthcoming development and introduction of a national EQA scheme in Croatia for the extra-analytical areas of testing must therefore be regarded as a great opportunity to improve the quality of the total testing process, inasmuch as those processes falling outside the analytical phase are much more vulnerable. This might be crucial for identifying critical points in laboratory activity and to systematically monitor all laboratory processes to prepare for the administratively demanding process of accreditation (21).
Recent years have seen a significant improvement in perceiving the importance of patient safety and the need to reduce the burden of preventable errors. Laboratory medicine is paving the way throughout a series of projects worldwide. Given that the primary obstacles are no longer technical, patient safety requires however a multifaceted approaches, encompassing total control of activities, from test request to results reporting. As such the time has come to think outside our traditional laboratory “box”, and target those extra-analytical processes that are more vulnerable to errors.
1. Raslich MA, Markert RJ, Stutes SA. Selecting and interpreting diagnostic tests. Biochem Med 2007;17:151-61.
2. Plebani M, Lippi G. To err is human. To misdiagnose might be deadly. Clin Biochem 2009; Jul 14. [Epub ahead of print]
3. Lippi G, Guidi GC, Mattiuzzi C, Plebani M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med 2006;44:358-65.
4. Lippi G, Guidi GC. Risk management in the preanalytical phase of laboratory testing. Clin Chem Lab Med 2007;45:720-7.
5. Plebani M. Laboratory errors: How to improve pre- and post-analytical phases? Biochem Med 2007;17:5-9.
6. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008;34:612-34.
7. Lippi G. Governance of preanalytical variability: travelling the right path to the bright side of the moon? Clin Chim Acta 2009;404:32-6.
8. Bilic-Zulle L, Simundic AM, Supak Smolcic V, Nikolac N, Honovic L. Self reported routines and procedures for the extra-analytical phase of laboratory practice in Croatia - cross-sectional survey study. Biochem Med 2010;20:64-74.
9. Lippi G, Montagnana M, Giavarina D; Italian Society of Clinical Biochemistry and Clinical Molecular Biology; Italian Society of Laboratory Medicine; Italian Committee for Standardisation of Laboratory and Haematological Methods. National survey on the pre-analytical variability in a representative cohort of Italian laboratories. Clin Chem Lab Med 2006;44:1491-4.
10. Likert R. A technique for the measurement of attitudes. Arch Psychol 1932;140:1–55.
11. Burnett D, Ceriotti F, Cooper G, Parvin C, Plebani M, Westgard J. Collective opinion paper on findings of the 2009 convocation of experts on quality control. Clin Chem Lab Med 2009; Nov 18. [Epub ahead of print]
12. Westgard JO. Managing quality vs. measuring uncertainty in the medical laboratory. Clin Chem Lab Med 2009; Nov 18. [Epub ahead of print]
13. Simundic AM, Topic E. Quality indicators. Biochem Med 2008;18: 311-9.
14. Sciacovelli L, Plebani M. The IFCC Working Group on laboratory errors and patient safety. Clin Chim Acta 2009;404:79-85.
15. Lippi G, Mattiuzzi C, Plebani M. Event reporting in laboratory medicine. Is there something we are missing? MLO Med Lab Obs 2009;41:23.
16. Lippi G, Plebani M. The importance of incident reporting in laboratory diagnostics. Scand J Clin Lab Invest 2009; Nov 23. [Epub ahead of print]
17. Challand GS, Li P. The assessment of interpretation of test results in laboratory medicine. Biochem Med 2009;19:146-53.
18. Alsina MJ, Alvarez V, Barba N, Bullich S, Cortés M, Escoda I, Martínez-Brú C. Preanalytical quality control program - an overview of results (2001-2005 summary). Clin Chem Lab Med 2008;46:849-54.
19. Lippi G, Luca Salvagno G, Blanckaert N, Giavarina D, Green S, Kitchen S, et al. Multicenter evaluation of the hemolysis index in automated clinical chemistry systems. Clin Chem Lab Med 2009;47:934-9.
20. Plebani M, Lippi G. Hemolysis index: quality indicator or criterion for sample rejection? Clin Chem Lab Med 2009;47:899-902.
21. Sierra-Amor RI, Lopez-Martinez M. Medical Laboratory Accreditation according to ISO 15189:2003. The Mexican Experience. Biochem Med 2007;17:188-92.